Maze Therapeutics, Inc. Annual Report: A Year in Review

I’ve put together this guide to help you understand how Maze Therapeutics performed this year. My goal is to explain their financial filings in plain English so you can decide if this company fits your investment goals.

1. What does the company do?

Maze Therapeutics acts like "genetic detectives." They use a platform called "Compass" to analyze human genetic data to find variations that protect against disease, which they then use to develop new treatments. 2025 was a landmark year, as they went public on the Nasdaq under the ticker "MAZE."

2. Financial performance

Maze is in the research-heavy biotech phase. They aren't selling products yet, so they are currently operating at a loss. For 2025, they reported a loss of about $148.2 million. Their income comes from partnerships, such as their deal with Neurocrine Biosciences, which brought in $15.5 million in research milestones in 2025 and could lead to $600 million in future milestone payments and royalties.

3. Major wins and challenges

The biggest win was going public, which raised about $150 million. As of March 2026, there were 49.7 million shares outstanding. Their success is tied to clinical trials; if they fail to meet their goals, they lose the milestone payments needed to cover their $160 million in annual operating costs.

4. Financial health

Maze is currently spending more than it earns, burning through about $10 million to $12 million in cash each month. By the end of 2025, they held $215 million in cash and safe investments, supplemented by a $50 million credit facility.

5. Key risks

The primary risk is the "biotech gamble." Their stock price reacts sharply to clinical trial results, and if a drug candidate—such as those for Pompe disease or kidney disease—fails to show safety or efficacy, the company’s value could drop significantly. Additionally, they rely heavily on a few partners for revenue, and high interest rates increase the cost of borrowing for their research.

6. Competitive positioning

Maze stands out by using its "Compass" platform to study many diseases at once. By mimicking natural genetic protections, they aim to increase the probability of their drugs succeeding in trials compared to traditional research methods.

7. Leadership and transparency

CEO Jason Coloma, Ph.D., leads the company. To ensure transparency, executives use pre-scheduled trading plans to sell stock, which helps maintain good corporate governance.

8. Future outlook

The focus for 2026 is hitting clinical milestones. With $215 million in cash, management expects to have enough runway to fund operations into the second half of 2027. Success depends on moving lead drugs through mid-stage trials and securing new partnerships to grow revenue.

---

Investor Takeaway: Maze Therapeutics is a high-risk, high-reward biotech play. Because they are not yet profitable and rely on clinical trial outcomes, they are best suited for investors who are comfortable with volatility and have a long-term outlook on the potential of genetic medicine. Before investing, consider whether you believe in their "Compass" platform's ability to beat the industry average for drug development success.